PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): A randomised, double-blind, placebo-controlled trial - Raal, F J; Stein, E A; Dufour, R (The Lancet, 2015)